Antifungal susceptibility profile of clinical Fusarium spp. isolates identified by molecular methods

被引:171
作者
Alastruey-Izquierdo, Ana [1 ]
Cuenca-Estrella, Manuel [1 ]
Monzon, Araceli [1 ]
Mellado, Emilia [1 ]
Luis Rodriguez-Tudela, Juan [1 ]
机构
[1] Inst Salud Carlos III, Ctr Nacl Microbiol, Serv Micol, Madrid, Spain
关键词
elongation factor alpha; antifungal resistance; emerging moulds;
D O I
10.1093/jac/dkn022
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Objectives: To analyse the susceptibility pattern of a collection of Fusarium clinical isolates. Methods: The antifungal susceptibility pattern of 67 isolates of Fusarium was analysed. Strains were identified by morphological and molecular methods by means of sequencing elongation factor alpha. Results and conclusions: Six different species were identified. Fusarium solani was the most frequently isolated, followed by Fusarium oxysporum, Fusarium proliferatum and Fusarium verticilloides. Amphotericin B was the only drug with in vitro activity (range: 0.015-32 mg/L). The rest of the antifungals tested (itraconazole, voriconazole, ravuconazole, posaconazole and terbinafine) showed very poor activity against Fusarium, confirming the multiresistant nature of this genus.
引用
收藏
页码:805 / 809
页数:5
相关论文
共 30 条
[1]   Comparative evaluation of two different methods of inoculum preparation for antifungal susceptibility testing of filamentous fungi [J].
Aberkane, A ;
Cuenca-Estrella, M ;
Gomez-Lopez, A ;
Petrikkou, E ;
Mellado, E ;
Monzón, A ;
Rodriguez-Tudela, JL .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2002, 50 (05) :719-722
[2]  
[Anonymous], 1994, MOL BIOL PATHOGENIC
[3]   Universal in vitro antifungal resistance of genetic clades of the Fusarium solani species complex [J].
Azor, Monica ;
Gene, Josepa ;
Cano, Josep ;
Guarro, Josep .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2007, 51 (04) :1500-1503
[4]   Fusarium, a significant emerging pathogen in patients with hematologic malignancy: Ten years' experience at a cancer center and implications for management [J].
Boutati, EI ;
Anaissie, EJ .
BLOOD, 1997, 90 (03) :999-1008
[5]  
Clinical and Laboratory Standards Institute, 2005, M38A CLSI
[6]   Successsful voriconazole treatment of disseminated Fusarium infection in an immunocompromised patient [J].
Consigny, S ;
Dhedin, N ;
Datry, A ;
Choquet, S ;
Leblond, V ;
Chosidow, O .
CLINICAL INFECTIOUS DISEASES, 2003, 37 (02) :311-313
[7]   Head-to-head comparison of the activities of currently available antifungal agents against 3,378 Spanish clinical isolates of yeasts and filamentous fungi [J].
Cuenca-Estrella, M ;
Gomez-Lopez, A ;
Mellado, E ;
Buitrago, MJ ;
Monzon, A ;
Rodriguez-Tudela, JL .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2006, 50 (03) :917-921
[8]   In-vivo itraconazole resistance of Aspergillus fumigatus in systemic murine aspergillosis [J].
Dannaoui, E ;
Borel, E ;
Persat, F ;
Monier, MF ;
Piens, MA .
JOURNAL OF MEDICAL MICROBIOLOGY, 1999, 48 (12) :1087-1093
[9]  
DEHOOG G, 1995, ATLAS CLIN FUNGI, P380
[10]   Correlation between in-vitro susceptibility testing to itraconazole and in-vivo outcome of Aspergillus fumigatus infection [J].
Denning, DW ;
Radford, SA ;
Oakley, KL ;
Hall, L ;
Johnson, EM ;
Warnock, DW .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1997, 40 (03) :401-414